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Objective: To personalize the prognostication of post-stroke outcome using
MRI-detected cerebrovascular pathology, we sought to investigate the association
between the excessive white matter hyperintensity (WMH) burden unaccounted for by the
traditional stroke risk profile of individual patients and their long-term functional outcomes
after a stroke.
Methods: We included 890 patients who survived after an acute ischemic stroke from
the MRI-Genetics Interface Exploration (MRI-GENIE) study, for whom data on vascular
risk factors (VRFs), including age, sex, atrial fibrillation, diabetes mellitus, hypertension,
coronary artery disease, smoking, prior stroke history, as well as acute stroke severity,
3- to−6-month modified Rankin Scale score (mRS), WMH, and brain volumes, were
available. We defined the unaccounted WMH (uWMH) burden via modeling of expected
WMH burden based on the VRF profile of each individual patient. The association of
uWMH and mRS score was analyzed by linear regression analysis. The odds ratios of
patients who achieved full functional independence (mRS < 2) in between trichotomized
uWMH burden groups were calculated by pair-wise comparisons.
Results: The expected WMH volume was estimated with respect to known VRFs.
The uWMH burden was associated with a long-term functional outcome (β = 0.104,
p < 0.01). Excessive uWMH burden significantly reduced the odds of achieving full
functional independence after a stroke compared to the low and average uWMH burden
[OR = 0.4, 95% CI: (0.25, 0.63), p <0.01 and OR = 0.61, 95% CI: (0.42, 0.87), p
<0.01, respectively].
Conclusion: The excessive amount of uWMH burden unaccounted for by the traditional
VRF profile was associated with worse post-stroke functional outcomes. Further studies
are needed to evaluate a lifetime brain injury reflected in WMH unrelated to the VRF
profile of a patient as an important factor for stroke recovery and a plausible indicator of
brain health.
Keywords: white matter hyper intensity, stroke, brain health, brain vulnerability, post-stroke outcomes,
functional independence, functional outcome after acute stroke, acute ischemic stroke
INTRODUCTION
The ability of the brain to recover after an acute ischemic
stroke (AIS) is linked to the pre-stroke burden of white matter
hyperintensity (WMH), a neuroradiological biomarker of brain
health (1–6). However, there is a significant variability in
functional outcomes after AIS in association with WMH burden.
It has not been fully characterized taking into consideration
multiple clinical characteristics, such as age, sex, and other
vascular risk factors (VRFs), that comprise a “traditional” stroke
risk profile. Because those characteristics might be associated
with stroke outcomes and also with accumulatingWMH burden,
quantifying the WMH burden effect on functional outcomes
independent of clinical characteristics is challenging (2, 7–14).
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In addition to and compounded by age, a VRF profile is linked
to overall brain health as reflected in the WMH burden—
for example, an older patient with a history of hypertension
is likely to have a larger WMH volume and less likely to
achieve functional independence after AIS (2, 15). Prior studies
using standard multiple regression models had a limited success
in characterizing and quantifying an independent association
between conventionally measured WMH volume and post-
stroke outcome because the effects of confounding VRFs to
the association of WMH and post-stroke outcomes were not
explicitly accounted for (1, 2, 8, 9, 11, 12, 14, 15).
In this study, we hypothesized that the excessive portion of
WMH burden unaccounted for by the clinical characteristics
of an individual patient was an important indicator of brain
health: i.e., the unaccounted WMH (uWMH) burden would
show the clear association of the lifelong chronic brain damage
independent of the VRF profile of a patient and the post-
stroke functional outcomes, especially in achieving full functional
independence after stroke. To test this hypothesis, we first
defined the uWMH burden given the VRF profiles of patients
to extrinsically quantify the portion of WMH burden that was
independent of the VRF profiles. We then analyzed the uWMH
association with post-stroke functional outcomes leveraging a
large international multi-site cohort study for AIS, the MRI-
Genetics Interface Exploration (MRI-GENIE), for the analyses
and validation (16, 17).
METHODS
Standard Protocol Approvals,
Registrations, and Patient Consents
The image and clinical data were acquired from the MRI-GENIE
study (16). The MRI-GENIE study is a large international cohort
study of 19 sites, contributing 6,600 AIS patients with phenotypic,
radiographic, and genotypic data. Patients were recruited in a
hospital-based setting through Stroke Genetic Network (SiGN).
The informed and written consent forms, including sharing
of de-identified demographic, clinical phenotypic, and imaging
data, were obtained from all patients or their legally authorized
representative (18, 19). Each site received the approval of their
internal review board.
Data, Clinical Characteristics, and WMH
Quantification
Age, sex, atrial fibrillation (AF), diabetes mellitus (DM),
hypertension (HTN), coronary artery disease (CAD), smoking
(SMK), and prior stroke history (PS) were included as the clinical
characteristics of patients. Each vascular risk factor was recorded
as a binary variable at hospital admission. The acute stroke
severity of a patient was measured according to NIH Stroke Scale
(NIHSS) at hospital admission.
T2 FLAIR MR images were obtained within the first 24 h
from symptom onset. A more detailed description of the study
can be found in previous publications (16, 20). White matter
hyperintensity volume (WMHv) was quantified by a previously
described automatic WMH segmentation framework (20). The
framework consists of an automatic whole-brain extraction,
intensity normalization, and WMH segmentation that leverages
a deep neural network specifically for clinical grade T2-FLAIR
images. Total brain volume was quantified automatically by a
similar previously described framework (21). Both WMH and
total brain segmentation results were evaluated, and the quality
was controlled by experts and experienced raters. WMHv was
adjusted by the total brain volume and log-transformed to correct
its skewed distribution. The brain-volume-adjusted and log-
transformed WMHv will be denoted as WMHv for simplicity in
the rest of this paper.
Out of 6,600 patients, the complete clinical characteristics of
5,822 patients were reported. Acute stroke severity and long-
term functional outcome data were available for 1,097 patients
out of those 6,015 patients and measured by the acute NIHSS
and the 3- to 6-month modified Rankin Scale (mRS) scores,
respectively. After the quality control of WMH and total brain
segmentation, 924 AIS patients remained. Thirty-four patients
who did not survive after stroke at the time of the mRS score
evaluation were excluded from the analysis, which resulted in a
total of 890 patients. The patient selection and the criteria are
summarized in Figure 1.
Unaccounted WMH Burden
To measure uWMH independent of the VRF profile of a patient,
we first modeled the association of WMH burden and the profile
of the patient by multiple log-linear regression. Age, sex, AF, DM,
HTN, CAD, SMK, and PS were considered in the analysis as
explanatory variables, andWMHv was the target variable. NIHSS
was included in the analysis as well to account for the effect
of acute stroke severity on functional stroke outcomes for later
analyses. The normality of WMHv data of the AIS population
with respect to the multiple log-linear regression model was
tested by the Shapiro–Wilks test.
The expected burden of WMHwith respect to the VRF profile
of a patient was calculated as the trend of the multiple log-linear
regression model. The uWMH burden measured the amount of
WMH burden that was not accounted for by the clinical profile
of a patient, i.e., the residual WMH burden of the multiple log-
linear regression model—for example, a positive uWMH value
indicated that a patient had excessiveWMHv than expected from
her or his clinical profile, and negative means lower WMHv than
expected. The normality of uWMH burden was tested by the
Shapiro–Wilks test.
We analyzed the continuous association of uWMH burden
and post-stroke functional outcome measured by the 3- to 6-
month mRS score using the univariate linear regression model
for the continuous association between uWMH burden and
post-stroke functional outcomes.
We investigated how uWMH affected the possibility of
functional independence after stroke by trichotomized analysis.
We trichotomized patients into low, expected, and excessive
eMWH burden groups based on uWMH burden. We defined
the average group as patients within ±1 standard deviation
from the mean uWMH burden, which resulted in 68% of total
patients. The low and excessive uWMH burden groups were
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FIGURE 1 | Flow chart on patient selection and its criteria.
defined as lower and higher 16% of patients of the uWMHburden
distribution, respectively.
The dichotomized 3- to 6-month mRS score (mRS excellent:
mRS score 0–1, mRS moderate–poor: mRS score 2–6) was used
to measure functional independence after AIS. We dichotomized
the mRS scores to mRS excellent and mRS moderate–poor to
investigate the association of uWMH burden and full functional
independence after stroke. We calculated the pair-wise odds
ratios of patients who achieved full functional independence for
patients between all burden groups (e.g., low vs. expected, low
vs. excessive, and expected vs. excessive). The 95% confidence
interval and the statistical significance of the odds ratio were
calculated by the standard z-test to investigate if there was a
significant difference between the groups in achieving functional
independence after stroke.
We performed the subgroup analysis regarding acute stroke
severity by dividing the patients into mild and severe acute
stroke severity groups. We divided the patients with respect
to their acute NIHSS scores, with a threshold defined as the
third quartile (Q3) of the NIHSS scores of the population.
We performed the same trichotomized analysis of uWMH
burden and investigated the odds ratios of patient who achieved
full functional independence, defined as “excellent mRS” (with
residual non-disabling symptoms, mRS 1, or symptom-free,
mRS 0) between the uWMH burden groups of each acute
severity subgroup.
All statistical analyses were performed with Python SciPy 1.5.4
(22), Sci-kit Learn 0.23 (23), and StatsModel 0.12 packages (24).
RESULTS
Population Analysis
The population characteristics of the included patients are
summarized in the first column of Table 1. The multiple log-
linear regression model of WMHv with respect to all included
clinical characteristics (age, sex, AF, HTN, DM, CAD, PS, and
NIHSS) represented an expected WMHv, ŶWMHv, of a patient
with respect to the VRF profile of the patient. The regression
coefficients of the multiple log-linear regression model are
summarized in Table 2. The multiple log-linear model explained
43.3% of the total variation of WMHv (R2 = 0.433). The
uWMH burden was not correlated with any included clinical
characteristics: i.e., the correlation coefficients of the uWMH
burden to all included clinical characteristics were 0. The uWMH
burden passed the normality test by the Shapiro–Wilks test (p <
0.001). The uWMH burden showed a significant association
with continuous functional outcomes (3-month to 6-month mRS
score: 0–5) in the univariate linear regression model β =
0.104, p < 0.01.
The second to the fourth columns of Table 1 summarize the
population characteristics of the low, expected, and excessive
uWMH burden groups. The averages of the uWMH burden of
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TABLE 1 | Population clinical characteristics of total acute ischemic stroke patients from the MRI-GENIE study and those included the analysis with available admission
NIHSS, 3- to 6-month mRS scores and WMHv, and the low, expected, and excessive uWMH burden groups.
Total (n = 5,822) Total included in the analysis (n = 890) Low (n = 140) Expected (n = 599) Excessive (n = 151)
Age, average (SD) 61.3 (15.2) 63.7 (15.0) 61.6 (14.1) 64.1 (15.5) 64.2 (13.9)
Sex, n (%) 2,416 (41.5%) 379 (42.6%) 59 (42.1%) 251 (41.9%) 69 (45.7%)
HTN, n (%) 3,849 (66.1%) 541 (60.8%) 88 (62.9%) 355 (59.3%) 98 (64.9%)
DM, n (%) 1,480 (25.4%) 180 (20.2%) 24 (17.1%) 131 (21.9%) 25 (16.6%)
AF, n (%) 741 (12.7%) 140 (15.7%) 19 (13.6%) 98 (16.4%) 23 (15.2%)
CAD, n (%) 1,021 (17.5%) 140 (15.7%) 13 (9.3%) 105 (17.5%) 22 (14.6%)
SMK, n (%) 3,342 (57.4%) 475 (53.4%) 70 (50.0%) 331 (55.3%) 74 (49.0%)
PS, n (%) 749 (12.9%) 85 (9.6%) 13 (9.3%) 59 (9.8%) 13 (8.6%)
NIHSS, median (IQR) N/A 3 (5) 3 (4) 3 (6) 3 (5)
uWMH, avg (std) N/A 0 (1.1) −1.8 (0.5) 0.0 (0.6) 1.6 (0.4)
TABLE 2 | The regression coefficients of individual univariate and multiple log-linear regression analyses that modeled the associations of age, sex, VRFs, and NIHSS with
WMHv.
Y = WMHv Age Sex HTN AF CAD DM SMK PS NIHSS β0
Regression coefficients 0.06 −0.19 0.33 −0.01 −0.1 0.27 0.30 0.33 0.01 −9.82
p <0.01 0.01 <0.01 0.96 0.4 <0.01 <0.01 0.01 0.08 <0.01
TABLE 3 | The odds ratios of patients who achieved full functional independence
(mRS excellent: mRS scores 0–1) of the excessive uWMH burden groups to the
low (excessive/low) and expected (excessive/expected) groups and of the
expected group to the low (expected/low) group.
Population Excessive/low Excessive/expected Expected/low
OR 0.39 0.6 0.65
p, 95% CI <0.01 (0.25, 0.63) <0.01 (0.42, 0.87) 0.03 (0.44, 0.96)
low, expected, and excessive eWMH burden groups were −1.8,
0.0, and 1.6, respectively.
The ratios of patients who achieved full functional
independence (mRS excellent: mRS score 0–1) in the low,
expected, and excessive uWMH burden groups were 65.7, 55.6,
and 43%, respectively. The odds ratios of the mRS excellent
patients between the uWMH burden groups are summarized
in Table 3. Patients in the excessive uWMH burden groups
were less likely to achieve full functional independence after
AIS than the expected and excessive uWMH burden groups.
The odds ratios of the excessive uWMH group with respect
to the expected and low uWMH burden groups were 0.604
(p < 0.01) and 0.394 (p < 0.01), respectively. The odds
ratio of the expected uWMH burden group with respect
to the low group was 0.653 (p = 0.03). Figure 2A shows
the distributions of mRS scores of the low, expected, and
excessive uWMH burden groups. The distribution of mRS
scores of the excessive uWMH burden groups was consistently
shifted toward worse mRS scores compared to the lower
uWMH groups.
As an auxiliary analysis, we conducted the same analyses
with all patients, including 34 post-stroke non-survivors (mRS
= 6). The results did not change substantially by including non-
survivors. The uWMH burden showed a significant association
with functional outcomes (3-month to 6-month mRS score: 0–
6) in the univariate regression model, β = 0.091, p = 0.036.
The odds ratios between the low, expected, and excessive uWMH
burden groups did not change substantially from the analysis
with post-stroke survivors only. The detailed results are reported
in Supplementary Tables 1–3 in the Supplementary Materials.
Acute Stroke Severity Subgroup Analysis
The third quartile of the NIHSS scores of the population was
seven. The median NIHSS scores of the mild (NIHSS <7) and
severe (NIHSS≥7) acute stroke severity subgroups were 2 and 11,
respectively. The overall population characteristics of the acute
stroke severity subgroups are summarized in Table 4.
In the mild acute stroke severity subgroup, the ratios of mRS
excellent patients in the low, expected, and excessive uWMH
burden groups were 71, 65.2, and 52.3%, respectively. The odds
ratios of the mRS excellent patients in the excessive uWMH
burden group with respect to the low and expected uWMH
burden groups were 0.446 (p < 0.01) and 0.585 (p = 0.01),
respectively. The odds ratio of the expected uWMH burden
group compared to the low uWMH burden group was 0.763
(p = 0.25).
In the severe acute stroke severity subgroup, the ratios of mRS
excellent patients in the low, expected, and excessive uWMH
burden groups were 48.5, 27.2, and 17.5%, respectively. The odds
ratios of the mRS excellent patients in the excessive and expected
uWMH burden groups with respect to the low uWMH burden
group were 0.225 (p < 0.01) and 0.396 (p = 0.02). The odds ratio
of the excessive uWMH burden group compared to the expected
uWMH burden group was 0.569 (p = 0.21). The odds ratios of
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FIGURE 2 | (A) The distribution of the modified Rankin Scale (mRS) scores of patients in the low, expected, and excessive unaccounted white matter hyperintensity
(uWMH) burden groups. The proportions of mRS scores were shifted toward worse mRS scores for the higher uWMH burden groups. (B) The acute stroke severity
subgroup analysis. The proportion of patients who achieved the full functional independence (mRS excellent: mRS 0 and 1) in each uWMH burden group was plotted
in blue and in red for the mild [NIH Stroke Scale (NIHSS) <7] and severe (NIHSS ≥7) acute stroke severity groups, respectively.
TABLE 4 | Population clinical characteristics of acute ischemic stroke patients in
the mild acute stroke severity group (mild, NIHSS < 7) and severe stroke severity
group (severe, NIHSS ≥ 7).
Mild (n = 666) Severe (n = 224)
Age, average (SD) 63.4 (15.2) 64.6 (14.3)
Sex, n (%) 273 (41.0%) 106 (47.3%)
HTN, n (%) 408 (61.3%) 133 (59.4%)
DM, n (%) 134 (20.1%) 46 (20.5%)
AF, n (%) 86 (12.9%) 54 (24.1%)
CAD, n (%) 95 (14.3%) 45 (20.1%)
SMK, n (%) 367 (55.1%) 108 (48.2%)
PS, n (%) 63 (9.5%) 22 (9.8%)
NIHSS, median (IQR) 2 (3) 11 (7)
uWMH, average (SD) 0.0 (1.1) 0.0 (1.1)
the subgroup analysis are summarized in Table 5 and visualized
in Figure 2B.
We also conducted an auxiliary analysis with all
patients, including the post-stroke non-survivors for
the subgroup analysis. The odds ratios and p-values
between the low, expected, and excessive uWMH burden
groups were not changed substantially for both mild
and severe acute stroke severity patients. The detailed
results are summarized in Supplementary Tables 4, 5 in
the Supplementary Materials.
TABLE 5 | Acute stroke severity subgroup analysis.






Mild (n = 666) OR 0.45 0.58 0.76





Severe (n = 224) OR 0.23 0.57 0.40





The odds ratios of patients who achieved full functional independence (mRS excellent:
mRS scores 0–1) of the excessive uWMH burden groups to the low (excessive/low)
and expected (excessive/expected) groups and of the expected group to the low
(expected/low) group in the mild acute stroke severity group (mild, NIHSS < 7) and the
severe acute stroke severity group (severe, NIHSS ≥ 7).
DISCUSSION
In this study, we analyzed the association of uWMH, i.e.,
the amount of WMH burden that is not explained by the
traditional VRFs of a patient, and post-stroke functional
outcome. Our results showed that, in stroke survivors, uWMH
was significantly associated with the 3–6 months of functional
outcomes. Furthermore, our population analysis showed that
patients with higher uWMH burden were less likely to achieve
full functional independence (mRS < 2) than patients with
lower uWMH burden, while their clinical characteristics were
similar. Our study supports the previous suggestions that WMH
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severity implicates more than the effects of demographics
and traditional VRFs and shows the clear association of the
uWMH burden and complete post-stroke functional recovery,
with the uWMH burden emerging as a new independent
variable to utilize in future analyses of post-stroke functional
outcomes (25).
The consistent results of the trichotomized analysis with
respect to the uWMH burden on the entire population showed
that excessive uWMH burden was linked to less probability
of achieving full functional independence and the opposite for
low uWMH. The mean uWMH burden of patients in the low
uWMH burden group was negative; thus, patients in the low
uWMH group had lower WMH severity than expected from
their demographics and traditional VRF profiles. This might
indicate that those patients who were more resilient to a lifelong,
chronic damage to the brain (as measured by WMH severity)
were more likely to achieve full functional independence after
stroke than those with similar VRF profiles but unexpectedly
excessive uWMH. The consistent finding that patients in the
excessive uWMH burden group were less likely to achieve full
functional independence compared to those in the other groups
also supports this interpretation.
The subgroup analysis based on acute stroke severity
showed that the uWMH burden was linked to full functional
independence for patients with both mild and severe acute
stroke severity. Because our patient population had milder acute
stroke severity (median NIHSS = 3) than a typical clinical
scenario of mixed mild and severe strokes, separate subgroup
analyses, including mild acute (median NIHSS = 2) and
severe (median NIHSS = 11) strokes, provided additional
information on the uWMH association with full functional
independence after stroke (mRS 0–1). The results were consistent
with the overall population analysis; excessive uWMH burden
in these subgroups resulted in a decreased probability of
achieving full functional independence and the opposite for
low uWMH.
In the severe stroke subgroup, patients with low uWMH
showed significantly greater odds of achieving full functional
independence after stroke than any others. In the mild stroke
group, the odds of achieving full functional independence by
patients with excessive uWMHwas significantly lower compared
to other groups. These findings might indicate that a patient
with the brain resilient to chronic cerebrovascular injury is
more robust to achieve full functional recovery even after
severe stroke, while a patient with a vulnerable brain (as
reflected by excessive uWMH) is more susceptible to post-stroke
disability even after a mild stroke (as shown in Figure 2B).
The additional finding to highlight with regard to these data is
that the probability of achieving full functional independence
post-stroke (mRS 0–1) in mild stroke patients with excessive
uWMH and the probability of those with low uWMH burden
and severe stroke were similar at 52.3 and 48.5%, respectively
(Table 5 and Figure 2B). We interpret these data as potential
evidence of the strong effect by uWMH on the functional
outcome in patients with different levels of acute stroke severity.
The excessive uWMH burden was more predictive on lower
functional outcomes for those with mild stroke severity and, on
the other hand, the low uWMH burden was more protective
on achieving functional independence for those with severe
stroke severity.
The uWMH burden was not correlated with any of the other
included clinical characteristics. This was expected since uWMH
represent residuals of the multiple log-linear regression model
with respect to the clinical characteristics. The multiple log-
linear regression modeling of WMHv and the other clinical
characteristics and the definition of the uWMH burden as the
residual of the model can be interpreted as the adjustment of
the effects of the demographics and traditional VRF profile
of a patient to the WMHv. The uWMH burden analysis
enabled the explicit exploration of the association between
WMH severity and post-stroke functional outcomes, free of the
traditional VRF patient profile effect (26). We only included the
univariate linear regression analysis for the uWMH association
with the continuous post-stroke functional outcome because
the uWMH burden was not correlated with the included
clinical factors.
There are several limitations of our study that are worth
considering for further investigations. The clinical characteristics
that were considered in this analysis were not exhaustive of
all known factors associated with WMH and stroke outcomes.
WMH accumulation depends on many factors: normal aging
(27), VRF aggregation, blood–brain barrier disruption (28),
amyloid and tau accumulation (29), hyperlipidemia (8, 14),
hyperhomocysteinemia (30), and genetics (31). Because the
uWMH burden captured the effects of the demographics
and traditional VRFs in a stroke cohort by modeling, it
might have captured the effect of unmeasured risk factors,
including the aforementioned VRFs, stroke etiologies, or
genetics. The binary representations of the traditional VRFs
may have undermined their effects on the WMH burden.
The additional information on a time-based load of VRFs
may improve the estimation of the expected WMH burden
based on the clinical characteristics of the patients and the
quantification of the unaccounted WMH burden. The education
and personal lifestyle of a patient that may also be related to
the WMH accumulation will improve the personalized analysis
on the association of the WMH burden and functional stroke
outcomes. The other possible risk factors will need to be
investigated further by other studies that specifically focus on
non-traditional risk factors for WMH and that may explain
the remaining unexplained variance of functional outcomes in
this study.
The post-stroke treatment information of patients was not
included in the analysis because the information was not
available in our study. The post-stroke treatment information
will enable a stratified analysis on patients who received
post-stroke treatments and those did not, with a careful
assessment on the heterogeneity of post-stroke treatments and
their complications. The cognitive decline of a patient will
also provide an important insight on the interaction between
the WMH burden and functional outcomes that can be
investigated further.
Patients in the low uWMH burden group were slightly
younger than the expected and excessive uWMH burden groups.
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Patients in the low uWMH burden groups were also less likely
to have DM, AF, CAD, and smoking than the expected uWMH
groups. Although the differences were not large, it might have
affected the results. However, patients in the excessive uWMH
burden group also had less proportions of having histories of
DM, AF, CAD, and smoking, which might suggest that the
differences were caused by the relatively small sample sizes of
the low and excessive uWMH burden groups. It is worth to
note that categorizing patients with respect to WMHv would
have resulted in larger differences in clinical characteristic
distribution across the groups and further complicated the
interpretation on the association of WMH severity and post-
stroke outcomes.
Being focused on explaining functional outcomes, our analysis
does not expand to the predictive capacity of the uWMH
burden for post-stroke functional outcomes. Our analysis was
also not validated with an independent cohort because of
the availability. The strong association of the uWMH burden
with post-stroke functional outcomes suggests that the uWMH
burden could be of benefit for future clinical prediction models
of functional outcomes. We do not suggest the uWMH burden
as the strongest predictor of post-stroke functional outcomes.
As shown in the subgroup analysis regarding the acute stroke
severity, the acute NIHSS was a stronger predictor of post-
stroke functional outcomes. However, the subgroup analysis
also showed that the uWMH burden could complement the
prediction of functional outcomes with the admission NIHSS.
This will be an interesting research direction to investigate
further regarding the predictive capability of the uWMH burden,
combined with other risk factors including the acute stroke
severity, by using predictive modeling (e.g., logistic regression,
decision forests, deep learning models, etc.). The predictive
power of the uWMH burden and its association to functional
outcomes will be benefited from cross-validation across multiple
datasets and also from validation with a dataset from an
independent cohort.
To enable the analysis of WMHv with the largest possible
number of image data, we used the automatic segmentation
framework to obtain WMHv. Although the WMH segmentation
masks were validated quantitatively and qualitatively, we did
not have access to old and new stroke lesion outlines and
could hence not comprehensively account for either one
(20). It is therefore possible that stroke infarcts with WMH
similarity might have led to some inaccuracies in WMH
delineation. This effect might be especially pronounced in
patients with a high acute stroke severity and larger, or
multiple, old and new stroke infarcts. However, in view of
a median NIHSS of only three, the median size of stroke
infarcts is expected to be small, as is their impact on
WMHv estimation.
Lastly, WMHv and whole-brain volume were quantified
by a scalar abstract measure—volume. Future studies should
investigate how high-dimensional brain features, such as
WMH, in relation to different white matter subregions
and brain anatomical structures (e.g., white matter, striatal
complex, and ventricle), are associated with functional
post-stroke outcomes.
CONCLUSION
The excessive burden of WMH that was not accounted
for by the demographics and traditional VRFs of each
individual patient is associated with post-stroke functional
outcomes, especially with full functional independence after
stroke. Our analysis suggests that a lifetime injury to the
white matter that is not explained by traditional VRF profile
is an important factor for stroke recovery and a plausible
indicator of brain health. In the future, an individual risk
profile of an AIS patient and its relationship to WMH
should be considered in a personalized approach to post-stroke
outcome prediction.
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